Katerina Veverova
Overview
Explore the profile of Katerina Veverova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veverova K, Katonova A, Horakova H, Laczo J, Angelucci F, Hort J, et al.
Acta Neuropathol Commun
. 2025 Feb;
13(1):37.
PMID: 39972393
Maintaining cellular homeostasis by removing damaged and senescent mitochondria, a process termed mitophagy, is crucial in preventing Alzheimer's disease (AD) and represents a promising therapeutic target. Our previous research revealed...
2.
Bolsewig K, Willemse E, Sanchez-Juan P, Rabano A, Martinez M, Doecke J, et al.
Nat Commun
. 2025 Jan;
16(1):1139.
PMID: 39881147
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we...
3.
Jurasova V, Andel R, Katonova A, Veverova K, Zuntychova T, Horakova H, et al.
Alzheimers Res Ther
. 2024 Sep;
16(1):199.
PMID: 39242539
Background: There is initial evidence suggesting that biomarker neurogranin (Ng) may distinguish Alzheimer's disease (AD) from other neurodegenerative diseases. Therefore, we assessed (a) the discriminant ability of cerebrospinal fluid (CSF)...
4.
Zhang J, Wang H, Veverova K, Vyhnalek M, Fang E
Ageing Res Rev
. 2024 Jun;
99:102378.
PMID: 38876257
No abstract available.
5.
Veverova K, Laczo J, Katonova A, Horakova H, Matuskova V, Angelucci F, et al.
Autophagy
. 2024 May;
20(8):1868-1878.
PMID: 38695174
Defective mitophagy is consistently found in postmortem brain and iPSC-derived neurons from Alzheimer disease (AD) patients. However, there is a lack of extensive examination of mitophagy status in serum or...
6.
cihak M, Horakova H, Vyhnalek M, Veverova K, Matuskova V, Laczo J, et al.
Arch Clin Neuropsychol
. 2024 Apr;
39(7):839-848.
PMID: 38582748
Objective: This study aims to evaluate the efficacy of the Uniform Data Set (UDS) 2 battery in distinguishing between individuals with mild cognitive impairment (MCI) attributable to Alzheimer's disease (MCI-AD)...
7.
Angelucci F, Veverova K, Katonova A, Vyhnalek M, Hort J
J Cell Mol Med
. 2024 Feb;
28(5):e18013.
PMID: 38386354
Plasminogen activator inhibitor-1 (PAI-1) impedes brain plasmin synthesis. Reduced plasmin activity facilitates cumulation of amyloid beta (Aβ) in Alzheimer's disease (AD). Since plasmin also regulates the synaptic activity, it is...
8.
Wang H, Siow R, Schmauck-Medina T, Zhang J, Sandset P, Filshie C, et al.
J Gerontol A Biol Sci Med Sci
. 2024 Jan;
79(4).
PMID: 38289789
Unhealthy aging poses a global challenge with profound healthcare and socioeconomic implications. Slowing down the aging process offers a promising approach to reduce the burden of a number of age-related...
9.
Matuskova V, Veverova K, Jester D, Matoska V, Ismail Z, Sheardova K, et al.
Alzheimers Res Ther
. 2024 Jan;
16(1):21.
PMID: 38279143
Background: Mild behavioral impairment (MBI) has been commonly reported in early Alzheimer's disease (AD) but rarely using biomarker-defined samples. It is also unclear whether genetic polymorphisms influence MBI in such...
10.
Angelucci F, Veverova K, Katonova A, Vyhnalek M, Hort J
ACS Omega
. 2023 Oct;
8(39):36025-36031.
PMID: 37810633
We previously demonstrated that serum levels of plasminogen activator inhibitor-1 (PAI-1), which inhibits both the tissue plasminogen activator (tPA) and plasmin activity, are increased in patients with Alzheimer's disease. tPA/plasmin...